Table 3.
Effect of EECT on CFA induced arthritis paw diameter (mean ± SEM, n = 6).
| Groups | Increase in paw diameter / mm |
||||
|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 7 | Day 14 | Day 21 | |
| Normal | 0.07 ± 0.009 | 0.093 ± 0.4 | 0.09 ± 0.0 | 0.12 ± 0.0 | 0.13 ± 0.0 |
| Arthritic control | 2.48 ± 0.208*** | 4.09 ± 0.3*** | 4.9 ± 0.4*** | 5.6 ± 0.2*** | 6.63 ± 0.4*** |
| CFA + Diclofenac (10 mg/kg) | 2.03 ± 0.2 ns | 3.10 ± 0.2 ns | 3.53 ± 0.5 ns | 2.86 ± 0.3*** | 2.91 ± 0.0*** |
| CFA + EECT (200 mg/kg) | 2.2 ± 0.3 ns | 3.800 ± 0.3 ns | 4.03 ± 0.6 ns | 3.8 ± 0.3* | 4.60 ± 0.4*** |
| CFA + EECT (400 mg/kg) | 2.43 ± 0.3 ns | 3.60 ± 0.4 ns | 3.93 ± 0.5 ns | 3.16 ± 0.4*** | 3.30 ± 0.2*** |
Statistical analysis was done by one-way analysis of variation (ANOVA) followed by Tukey’s multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.001 and ns- non significant. Arthritic control was compared with normal and the treated groups were compared with arthritic control.